Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

A new set of antibodies thanks to SupraAntigen
November 2017
SHARING OPTIONS:

LAUSANNE, Switzerland—Biopharmaceutical company AC Immune SA announced in the past few months that it had discovered new antibodies against a pair of targets linked to the pathogenesis of neurodegenerative diseases: alpha-synuclein, a target in Parkinson’s and other Lewy body diseases, and TDP-43, recently identified as a target of interest for neuro-orphan conditions such as frontotemporal lobar degeneration. These targets are also known to factor into Alzheimer’s disease. An AC Immune press release noted that the two new antibodies, discovered using AC Immune’s SupraAntigen platform, “complement the R&D collaboration with Biogen (announced April 2016) comprised of two radiopharmaceutical diagnostic programs to develop PET-ligands for both alpha-synuclein and TDP-43, using AC Immune’s proprietary Morphomer chemistry technology platform.” The company is working with expert groups to determine the antibodies’ exact mode of action.

Back



PAGE UTILITIES


CONTACT US
DDNEWS
478 Bay Street, Suite A213
Midland, Ontario, Canada L4R 1K9
Ph: 888-781-0328 |  Fax: 705-528-0270
 
© Copyright 2020 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.